Results 191 to 200 of about 33,878 (250)

Exosome‐Mediated Delivery of PROTACs for Targeted Protein Degradation in Cancer, Neurodegenerative, Infectious, and Inflammatory Diseases

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are heterobifunctional molecules that hijack the ubiquitin‐proteasome system to drive catalytic, sub‐stoichiometric degradation of disease‐associated proteins, offering a mechanistic advantage over occupancy‐driven inhibitors and access to ‘undruggable’ targets.
Sruti Bagchi Ghosh, Rumpa Banerjee, Hailah M. Almohaimeed, Amany I. Almars, Tahani Ahmad ALMatrafi, Fayez M. Saleh, Zuhair M. Mohammedsaleh, Kranti Kiran Reddy Ealla, Ajoy Kumer, Bikram Dhara   +9 more
wiley   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

EEG network reorganization across Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies. [PDF]

Alzheimers Dement (Amst)
Benussi A, Cantoni V, Palacino F, Altomare D, Moretti DV, Manganotti P, Borroni B.   +6 more
europepmc   +1 more source

Discriminative Plasma Lipidomic Signatures of Dementia with Lewy Bodies and Alzheimer's Disease: A Targeted Mass Spectrometry and Machine Learning Approach. [PDF]

Neuropsychiatr Dis Treat
Wen L, Zhang Y, Nie Y, Shen H, Qin Q, Qu M.   +5 more
europepmc   +1 more source

Implication of dopamine transporter and electroencephalography biomarkers in dementia with lewy bodies. [PDF]

Sci Rep
Baik K, Jeon S, Kang S, Kim Y, Kim KM, Heo K, Yun M, Ye BS.   +7 more
europepmc   +1 more source

Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB). [PDF]

Alzheimers Dement
Galvin JE, Tolea MI, Scharre DW, Hamby ME, Iaci JF, Grundman M, Caggiano AO.   +6 more
europepmc   +1 more source

Deep learning for FDG-PET classification in patients with Alzheimer's disease, dementia with Lewy bodies and their mixed pathology: a solution for diagnostic heterogeneity. [PDF]

Front Aging Neurosci
Kim S, Jeon S, Cho K, Kang S, Bang S, Ye BS, Lee JM.   +6 more
europepmc   +1 more source